Scarica l'app Stockscreener
11.18
2.78%
-0.32
Precedente Chiudi:
$11.50
Aprire:
$11.6
Volume 24 ore:
130.40K
Relative Volume:
0.10
Capitalizzazione di mercato:
$522.13M
Reddito:
$20.72M
Utile/perdita netta:
$-100.84M
Rapporto P/E:
-4.203
EPS:
-2.66
Flusso di cassa netto:
$-78.56M
1 W Prestazione:
-8.88%
1M Prestazione:
+30.76%
6M Prestazione:
+197.34%
1 anno Prestazione:
+38.11%
Intervallo 1D:
$11.15
$11.70
Intervallo di 1 settimana:
$11.09
$12.34
Portata 52W:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Nome
4 D Molecular Therapeutics Inc
Settore
Industria
Telefono
(510) 505-2680
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Confronta FDMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
11.18 | 537.08M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.60 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.72 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.82 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.12 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-13 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Iniziato | Morgan Stanley | Underweight |
| 2024-09-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Iniziato | Barclays | Overweight |
| 2024-02-07 | Ripresa | Goldman | Buy |
| 2023-10-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-01-30 | Iniziato | BMO Capital Markets | Outperform |
| 2022-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-12 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Iniziato | Jefferies | Buy |
| 2022-01-04 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Evercore ISI | Outperform |
| 2021-01-05 | Iniziato | Goldman | Neutral |
Mostra tutto
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
Backtesting results for 4D Molecular Therapeutics Inc. trading strategiesTrade Analysis Summary & Safe Swing Trade Setups - newser.com
Why 4D Molecular Therapeutics Inc. stock remains on watchlistsDollar Strength & Weekly Top Performers Watchlists - newser.com
Is 4D Molecular Therapeutics Inc. stock ready for a breakoutMarket Activity Recap & Entry Point Confirmation Alerts - newser.com
4D Molecular Therapeutics Partners with Otsuka for APAC Market - MSN
4D Molecular Therapeutics (FDMT) Stock: Soars on $85M Otsuka Deal to Expand 4D-150 Across APAC - parameter.io
4D Molecular Shares Rise Premarket on Partnership With Otsuka - MarketScreener
4D Molecular (FDMT) Forms Key Partnership with Otsuka Pharmaceutical - GuruFocus
FDMT licenses 4D-150 in APAC to Otsuka with $85M upfront - Stock Titan
4D Molecular Therapeutics, Inc. Enters into Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd - MarketScreener
4D Molecular Therapeutics Announces Strategic Partnership with Otsuka Pharmaceutical Co. Ltd. to Develop and Commercialize 4D-150 for Treatment of Wet AMD and DME in APAC Region Including Japan - MarketScreener
4D Molecular Therapeutics Announces Strategic Partnership with Otsuka for Development of 4D-150 in Asia-Pacific Markets - Quiver Quantitative
4DMT (NASDAQ: FDMT) licenses 4D-150 to Otsuka in APAC; $85M upfront, $336M milestones - Stock Titan
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific - Yahoo Finance
How institutional ownership impacts 4D Molecular Therapeutics Inc. stockTreasury Yields & Daily Chart Pattern Signal Reports - newser.com
4D Molecular Therapeutics, Inc. (FDMT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
4D Molecular Therapeutics, Inc. (FDMT) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
4D Molecular Therapeutics Advances Gene Therapy Trial for Fabry Disease - MSN
4D Molecular Therapeutics Advances Phase 3 Trial for Vision Loss Treatment - MSN
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
Applying big data sentiment scoring on 4D Molecular Therapeutics Inc.2025 Dividend Review & Community Supported Trade Ideas - newser.com
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Will 4D Molecular Therapeutics Inc. stock see insider buying2025 Stock Rankings & Proven Capital Preservation Methods - fcp.pa.gov.br
What is the fair value of 4D Molecular Therapeutics Inc. stock now2025 Biggest Moves & AI Driven Stock Reports - newser.com
4D Molecular Therapeutics Executive Sells Shares - TradingView
FDMT insider trade: options at $6.49, sale at $12 on 10/24/2025 - Stock Titan
4D Molecular Therapeutics Advances Gene Therapy for Wet AMD - TipRanks
4D Molecular Therapeutics Advances Gene Therapy Trial for Cystic Fibrosis - TipRanks
Published on: 2025-10-26 19:59:33 - newser.com
4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - Insider Monkey
4D Molecular Therapeutics’ (FDMT) “Outperform” Rating Reiterated at Royal Bank Of Canada - Defense World
Can 4D Molecular Therapeutics Inc. stock resist sector downturnsWeekly Profit Report & Free Real-Time Volume Trigger Notifications - newser.com
RBC Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT) - The Globe and Mail
RBC Capital Reiterates 4D Molecular Therapeutics (FDMT) Outperform Recommendation - Nasdaq
What recovery options are there for 4D Molecular Therapeutics Inc.Risk Management & Expert Approved Momentum Trade Ideas - newser.com
How to build a dashboard for 4D Molecular Therapeutics Inc. stockOptions Play & Free Expert Verified Stock Movement Alerts - newser.com
Bizily, 4D Molecular Therapeutics CLO, sells $16,627 in FDMT stock - Investing.com India
Bizily, 4D Molecular Therapeutics CLO, sells $16,627 in FDMT stock By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics insider trade under 10b5-1 plan - Stock Titan
Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High? - MSN
Does 4D Molecular Therapeutics Inc. stock trade at a discount to peers2025 Pullback Review & Reliable Momentum Entry Alerts - nchmf.gov.vn
Will 4D Molecular Therapeutics Inc. stock benefit from AI adoption2025 Top Gainers & Real-Time Chart Pattern Alerts - nchmf.gov.vn
Leerink Partnrs Issues Optimistic Estimate for FDMT Earnings - Defense World
How 4D Molecular Therapeutics Inc. stock responds to policy changesTrade Volume Report & Free Growth Oriented Trading Recommendations - Trung tâm Dự báo KTTV quốc gia
4DMT Announces New Employment Inducement Grants - GlobeNewswire
4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.21%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):